| Description | Gemcabene (PD-72953) is a lipid-lowering agent with anti-inflammatory activity. Gemcabene lowers low-density lipoprotein cholesterol and triglycerides, raises high-density lipoprotein cholesterol, and decreases pro-inflammatory acute-phase protein, C-reactive protei |
| In vitro | Gemcabene 显著降调肝脏炎症标志物的 mRNA 表达，包括 TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB。Gemcabene 抑制脂肪合成和纤维化相关基因，如 TIMP-1 和 MMP-2。Gemcabene 调节脂质代谢相关基因，包括 ApoC-III, ACC1, ADH-4 和 Sulf-2[2]。 |
| Synonyms | PD-72953 |
| molecular weight | 302.41 |
| Molecular formula | C16H30O5 |
| CAS | 183293-82-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 95 mg/mL (314.14 mM), Sonication is recommended. |
| References | 1. Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471. 2. Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568. 3. Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. |